This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bioequivalence and Food Effect Study in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: June 29, 2007
Last updated: January 19, 2017
Last verified: January 2017
The purpose of this study is to select the formulation with the optimal pharmacokinetic profile for an hypnotic drug to further develop in the market.

Condition Intervention Phase
Sleep Initiation and Maintenance Disorders Insomnia Drug: SB-649868 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Single-centre, Open-label, Randomized, Single-dose, 6-way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 6 Different Formulations of SB-649868 30 mg (Part A) and the Effect of Food on the Selected Formulation of SB-649868 Pharmacokinetic (Part B) in Healthy Male Volunteers

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • -Part A: SB-649868 levels of 6 formulation predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose [ Time Frame: predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose ]
  • -Part B: SB-649868 levels of selected formulation after food at the same timepoints as in Part A [ Time Frame: predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose ]

Secondary Outcome Measures:
  • -AE, Lab values and cardiovascular monitoring throughout study participation [ Time Frame: throughout study participation ]
  • -Romberg heel-to-toe test at discharge [ Time Frame: at discharge ]
  • -Cognitive functions predose, 0.5, 1, 2, 4, 6 hours post-dose [ Time Frame: predose, 0.5, 1, 2, 4, 6 hours post-dose ]
  • Pharmacodynamic endpoint: Bond Lader Visual Analogue Scale (VAS) score

Enrollment: 16
Study Start Date: July 2007
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Detailed Description:
A single-centre, open-label, randomized, single-dose, 6-way crossover study to investigate the pharmacokinetics, safety and tolerability of 6 different formulations of SB-649868 30 mg (Part A) and the effect of food on the selected formulation of SB-649868 pharmacokinetic (Part B) in healthy male volunteers

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Healthy adult male subjects aged between 18 and 65 years of age inclusive.
  • Body weight and BMI within the protocol ranges.
  • Healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests, cardiac monitoring.
  • Circulating levels of LH, FSH and testosterone within the normal reference range.
  • Signed and dated written informed consent.
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion criteria:

  • Positive pre-study urine drug screen and alcohol breath test.
  • Positive pre-study Hepatitis B surface antigen, Hepatitis C antibody, or HIV ½ result.
  • Abuse of alcohol as per protocol criteria.
  • Consumption of prohibited food and drink as per protocol.
  • Subject who is not prepared to eat the standard meals provided by the site.
  • Use of prescription or non-prescription drugs 1 or 2 weeks before the first dose of study medication.
  • Where participation in study would result in donation of blood in excess of 500mL within a 56 day period.
  • History or presence of allergy to the study drug or drugs of this class, or a history of other allergy.
  • Smoking history in the last three months as per protocol.
  • An unwillingness of male subjects to follow contraception methods as per protocol.
  • History or presence of significant psychiatric, respiratory or gastrointestinal illnesses, hepatic or renal diseases or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • The subject is unable or unwilling to abstain from strenuous physical activity in the 48 hours before screening and in the 48 hours before and the 48 hours after the treatment period.
  • Current or previous (within 6 months) participation in a clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00495274

GSK Investigational Site
Verona, Veneto, Italy, 37134
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00495274     History of Changes
Other Study ID Numbers: OXS105205
Study First Received: June 29, 2007
Last Updated: January 19, 2017

Keywords provided by GlaxoSmithKline:
Reference formulation
5 new formulation
Food effect

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders processed this record on July 21, 2017